Brief: Oncopeptides Q1 Operating Loss Narrows To SEK 98.9 Mln
May 4 (Reuters) - Oncopeptides AB ONCO.ST :
* ONCOPEPTIDES PUBLISHES Q1 REPORT 2022
* Q1 NET SALES AMOUNTED TO SEK 0.0 M (19.4)
* Q1 OPERATING LOSS WAS SEK -98.9 M (-347.3)
Source text for Eikon: ID:nWkr6793kG
Further company coverage: ONCO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy